Charpentier, Doudna, Jinek, and Chylinski filed the first-ever patent application for CRISPR-Cas9 gene editing across all cell types, a foundational moment in biotechnology history.
On May 25, 2012, Emmanuelle Charpentier, together with Jennifer Doudna, Martin Jinek, and Krzysztof Chylinski, filed the first patent application covering the CRISPR-Cas9 genome-editing system for use in all environments — including bacteria, plant, animal, and human cells. This filing followed directly from the team's landmark 2012 Science paper describing how the bacterial CRISPR-Cas9 immune system could be reprogrammed as a precise, programmable tool for cutting DNA at targeted locations.
The application, submitted to the U.S. Patent and Trademark Office, was later recognized by the University of California, Berkeley as the first-to-file application for the foundational CRISPR-Cas9 technology, predating competing claims by other research groups. This filing represented the critical legal and institutional acknowledgment that Charpentier and Doudna's team had originated the core innovation: a two-component RNA-guided DNA-cutting system dramatically simpler and more versatile than prior gene-editing tools like zinc-finger nucleases and TALENs.
The significance of this filing cannot be overstated — it set off years of complex patent disputes with the Broad Institute over commercial rights, while simultaneously cementing Charpentier and Doudna's place in history as co-inventors of a technology that would revolutionize biology, medicine, and agriculture. The patent battles that followed became one of the most closely watched intellectual property sagas in modern science, underscoring the immense commercial and humanitarian stakes of the invention. Ultimately, this filing was a pivotal early milestone en route to Charpentier and Doudna's shared 2020 Nobel Prize in Chemistry.